These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 35243548

  • 1. Sphingosine-1-phosphate receptor modulators versus interferon beta for the treatment of relapsing-remitting multiple sclerosis: findings from randomized controlled trials.
    Yang S, Li X, Wang J, Wang T, Xu Z, Gao H, Chen G.
    Neurol Sci; 2022 Jun; 43(6):3565-3581. PubMed ID: 35243548
    [Abstract] [Full Text] [Related]

  • 2. Patients' Preferences for Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis Based on Clinical Management Considerations: A Choice Experiment.
    Keenan A, Whichello C, Le HH, Kern DM, Fernandez GS, Turner V, Das A, Quaife M, Ross AP.
    Patient; 2024 Nov; 17(6):685-696. PubMed ID: 38748388
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
    Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L, RADIANCE Trial Investigators.
    Lancet Neurol; 2019 Nov; 18(11):1021-1033. PubMed ID: 31492652
    [Abstract] [Full Text] [Related]

  • 4. Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model.
    Corsten CEA, Huygens SA, Versteegh MM, Wokke BHA, Smets I, Smolders J.
    Mult Scler Relat Disord; 2023 Dec; 80():105100. PubMed ID: 37944195
    [Abstract] [Full Text] [Related]

  • 5. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A.
    Cochrane Database Syst Rev; 2016 Nov 24; 11(11):CD009333. PubMed ID: 27880972
    [Abstract] [Full Text] [Related]

  • 6. Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
    Roskell NS, Zimovetz EA, Rycroft CE, Eckert BJ, Tyas DA.
    Curr Med Res Opin; 2012 May 24; 28(5):767-80. PubMed ID: 22462530
    [Abstract] [Full Text] [Related]

  • 7. An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis.
    Dumitrescu L, Papathanasiou A, Coclitu C, Garjani A, Evangelou N, Constantinescu CS, Popescu BO, Tanasescu R.
    Expert Opin Pharmacother; 2023 Mar 24; 24(4):495-509. PubMed ID: 36946625
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
    Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA, SUNBEAM Study Investigators.
    Lancet Neurol; 2019 Nov 24; 18(11):1009-1020. PubMed ID: 31492651
    [Abstract] [Full Text] [Related]

  • 9. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis.
    Roy R, Alotaibi AA, Freedman MS.
    CNS Drugs; 2021 Apr 24; 35(4):385-402. PubMed ID: 33797705
    [Abstract] [Full Text] [Related]

  • 10. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A.
    Cochrane Database Syst Rev; 2014 Jul 26; (7):CD009333. PubMed ID: 25062935
    [Abstract] [Full Text] [Related]

  • 11. Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Sun Y, Yang Y, Wang Z, Jiang F, Chen Z, Wang Z.
    Front Pharmacol; 2020 Jul 26; 11():589146. PubMed ID: 33658933
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
    Hutchinson M, Fox RJ, Havrdova E, Kurukulasuriya NC, Sarda SP, Agarwal S, Siddiqui MK, Taneja A, Deniz B.
    Curr Med Res Opin; 2014 Apr 26; 30(4):613-27. PubMed ID: 24195574
    [Abstract] [Full Text] [Related]

  • 13. Rituximab for relapsing-remitting multiple sclerosis.
    He D, Guo R, Zhang F, Zhang C, Dong S, Zhou H.
    Cochrane Database Syst Rev; 2013 Dec 06; (12):CD009130. PubMed ID: 24310855
    [Abstract] [Full Text] [Related]

  • 14. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S, Rahimi R, Abdollahi M.
    Clin Ther; 2010 Oct 06; 32(11):1871-88. PubMed ID: 21095482
    [Abstract] [Full Text] [Related]

  • 15. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA, TRANSFORMS Study Group.
    Lancet Neurol; 2011 Jun 06; 10(6):520-9. PubMed ID: 21571593
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of peginterferon beta-1a compared to interferon beta-1a in relapsing remitting multiple sclerosis patients: A phase 3, randomized, non-inferiority clinical trial (PEGINTEGRITY).
    Shaygannejad V, Ashtari F, Saeidi M, Beladi Moghadam N, Ghalyanchi Langroodi H, Baghbanian SM, Abolfazli R, Ghiasian M, Ayromlou H, Asadollahzadeh E, Sabzvari A, Kafi H, Azimi Saeen A.
    Mult Scler Relat Disord; 2024 Oct 06; 90():105839. PubMed ID: 39217809
    [Abstract] [Full Text] [Related]

  • 17. Ozanimod for the treatment of relapsing remitting multiple sclerosis.
    Rasche L, Paul F.
    Expert Opin Pharmacother; 2018 Dec 06; 19(18):2073-2086. PubMed ID: 30407868
    [Abstract] [Full Text] [Related]

  • 18. Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more.
    Constantinescu V, Akgün K, Ziemssen T.
    Expert Opin Drug Metab Toxicol; 2022 Oct 06; 18(10):675-693. PubMed ID: 36260948
    [Abstract] [Full Text] [Related]

  • 19. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.
    Hennessy B, Zierhut ML, Kracker H, Keenan A, Sidorenko T.
    Mult Scler Relat Disord; 2022 Aug 06; 64():103908. PubMed ID: 35803162
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.